Brainstorm Cell Therapeutics Inc.
BCLI
$0.61
$0.000.51%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.15M | 1.45M | 1.79M | 1.47M | 2.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.05M | 2.57M | 3.09M | 3.19M | 3.05M |
| Operating Income | -2.05M | -2.57M | -3.09M | -3.19M | -3.05M |
| Income Before Tax | -2.11M | -2.90M | -2.86M | -2.97M | -2.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.11M | -2.90M | -2.86M | -2.97M | -2.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.11M | -2.90M | -2.86M | -2.97M | -2.71M |
| EBIT | -2.05M | -2.57M | -3.09M | -3.19M | -3.05M |
| EBITDA | -2.00M | -2.52M | -3.04M | -3.14M | -2.99M |
| EPS Basic | -0.19 | -0.34 | -0.45 | -0.52 | -0.51 |
| Normalized Basic EPS | -0.12 | -0.21 | -0.28 | -0.33 | -0.32 |
| EPS Diluted | -0.19 | -0.34 | -0.45 | -0.52 | -0.51 |
| Normalized Diluted EPS | -0.12 | -0.21 | -0.28 | -0.33 | -0.32 |
| Average Basic Shares Outstanding | 11.01M | 8.62M | 6.34M | 5.71M | 5.31M |
| Average Diluted Shares Outstanding | 11.01M | 8.62M | 6.34M | 5.71M | 5.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |